The takeover, which media reports value at about $45 million, gives Medtronic control of FDA-cleared systems for assessing motility disorders.

The takeover gives Edwards control of a technology to repair the hearts of patients with the degenerative form of mitral valve disease.

The project is built upon a device Rani designed to enable the oral delivery of proteins and other molecules that are currently injected.

LivaNova will pay $78 million and commit to almost $150 million more to buy the rest of ImThera and its neurostimulation treatment for sleep apnea.

The pact positions Biocartis to register its Idylla RAS tests as companion diagnostics for Amgen's colorectal cancer drug Vectibix. 

The court case follows Alere’s decision to sell its BNP assay business and associated supply agreements to Quidel to clear antitrust barriers.

Health chiefs will use the cash to hire ethical hackers to break into NHS computer systems and fix the vulnerabilities they expose.

LivaNova will sell its Cardiac Rhythm Management business to its joint venture partner, MicroPort Scientific.